Reasonable application of erythropoiesis-stimulating agents and iron supplements in patients with kidney diseases

doi:10.3877/cma.j.issn.2095-3216.2014.05.005

Abstract

Abstract:

Anemia is an important complication of patients with chronic kidney disease (CKD),whose main causes are reduction of renal erythropoietin (EPO) secretion and iron deficiency. The unreasonable application of erythropoiesis-stimulating agents (ESAs) and iron supplements can make the hemoglobin level too high or too low, which will lead to the occurrence of clinical adverse reactions. This review discussed about the reasonable use of ESAs and iron supplements according to the 2012 Kidney Disease: lmproving Global Outcomes (KDIGO) anemia treatment guidelines and the 2014 Chinese experts consensus of diagnosis and treatment of renal anemia, to remind clinicians to evaluate the risk and benefit of the treatment of anemia,to apply ESAs and iron supplements reasonably,to maintain the hemoglobin level in a safe target range, to avoid the side effects of anaemia management, and to individualize the treatment of anaemia.

Key words: Chronic kidney disease, Anemia, Erythropoiesis-stimulating agent, Iron supplement

Caili Wang. Reasonable application of erythropoiesis-stimulating agents and iron supplements in patients with kidney diseases[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2014, 03(05): 246-250.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2014.05.005

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2014/V03/I05/246

References 21

1	陆再英,钟南山.内科学[M]北京:人民卫生出版社,2008:567.
2	中国医师协会肾内科医师分会肾性贫血诊断和治疗共识专家组.肾性贫血诊断与治疗中国专家共识(2014 修订版)[J].中华肾脏病杂志,2014,30(9):712-716.
3	Lee YT, Chiu HC, Su HM,et al. Lower hemoglobin concentrations and subsequent decline in kidney function in an apparently healthy population aged 60 year and older [J]. Clin Chim Acta, 2008,389:25-30.
4	Port FK, Pisoni RL, Bommer J, et al. Improving outcomes for dialysis patients in the international dialysis outcomes and practice patterns study. Clin J Am Soc Nephrol,2006,1(2):246-255.
5	Portolés J, López-Gómez JM, Aljama P. A prospective multicentre study of the role of anaemia as a risk factor in haemodialysis patients:The MAR Study [J]. Nephrol Dial Transplant,2007,22(2):500-507.
6	Locatelli F, Vecchio L,Pozzoni P. Anemia and cardiovascular risk:the lesson of the CREATE Trial [J]. J Am Soc Nephrol,2006,17(12 Suppl 3): S262-S266.
7	Goldsmith D,Covic A. Time to Reconider Evidence for Anaemia Treatment(TREAT) = Essential Safety Arguments (ESA) [J].Nephrol Dial Transplant,2010,25(6):1734-1737.
8	Regidor DL,Kopple JD,Kovesdy CP. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients [J]. J Am Soc Nephrol,2006,17(4):1181-1191.
9	McMurray JJV, Parfrey PS. KDIGO Clinical Practice Guideline Working Group. KDIGO clinical practice guideline for anemia in chronic kidney disease [J]. Kidney Int,2012,2( Suppl 4):279-335.
10	Unger EF, Thompson AM, Blank MJ, et al. Erythropoiesisstimulating agents--time for a reevaluation [J]. N Engl J Med,2010,362(3):189-192.
11	Loughnan A, Ali GR, Abeygunasekara SC. Comparison of the therapeutic efficacy of epoetin beta and epoetin alfa in maintenance phase hemodialysis patients [J]. Renal Failure, 2011, 33(3):373-375.
12	Servilla KS, Singh AK, Hunt WC, et al. Anemia management and association of race with mortality and hospitalization in a large notfor-profit dialysis organization [J]. Am J Kidney Dis, 2009, 54(3):498-510.
13	Zhang Y, Thamer M, Kaufman JS, et al. High doses of epoetin do not lower mortality and cardiovascular risk among elderly hemodialysis patients with diabetes[J]. Kidney Int,2011,80(6):663-669.
14	Lestz RM, Fivush BA, Atkinson MA. Association of higher erythropoiesis stimulating agent dose and mortality in children on dialysis [J]. Pediatr Nephrol,2014,29(10):2021-2028.
15	Vaziri ND, Zhou XJ. Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease [J]. Nephrol Dial Transplant,2009,24(4):1082-1088.
16	U.S. Food and Drug Administration. FDA modifies dosing recommendations for Erythropoiesis-Stimulating Agents [EB/OL].[2011-06-27]. http: / /www. fda. gov /newsevents /newsroom /pressannouncements/ucm.260670.htm.
17	Sinsakul M, Rodby R, Umanath K, el at. Ferric citrate spans mineral metabolism and anemia domains in ESRD: a review of efficacy and safety data [J]. Expert Rev Clin Pharmacol, 2014, 7(6):705-710.
18	Schwenk MH. Ferumoxytol:a new intravenous iron preparation for the treatment of iron deficiency anemia in patients with chronic kidney disease [J]. Pharmacotherapy,2010,30(1):70-79.
19	Qunibi WY1, Martinez C, Smith M, et al. A randomized controlled trial comparing intravenous ferriccarboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients[J]. Nephrol Dial Transplant,2011,26(5):1599-1607.
20	林攀,刘中华,邹建洲, 等. 上海市透析患者贫血治疗现况调查[J].肾脏病与透析肾移植杂志,2011,20(4):332-337.
21	Bailie GR. Comparison of rates of reported adverse events associated with i.v. iron products in the United States [J]. Am J Health Syst Pharm,2012,69(4):310-320.

[1]	Xiaoqing Tang, Ping He, You Yang, Xia Luo, Juying Zhang, Xin Yang, Jinhong Yu. Correlation of sound touch elastography combined with pulsed wave Doppler ultrasound imaging parameters with stage of early chronic kidney disease and their clinical significance [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2024, 21(05): 491-499.
[2]	Jiangyan Xie, Yafei Wang, Fang He. Pregnancy complicated with thrombotic thrombocytopenic purpura：two cases report and literature review [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2024, 20(05): 556-563.
[3]	Jiayu Xu, Fuhua Zhang, Guomin Niu, Jiabao Liang, Huanyu Pan, Xiuqu Mai, Guolei Yang, Jialiang Xu, Youyong Huang. Application of Th1/Th2 cytokine profile in patients with malignant hematologic tumors with agranulocytosis and infection after chemotherapy [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2024, 14(03): 143-150.
[4]	Shuxun Ling, Yue Tu, Siyi Liu. Visualization analysis on knowledge map of mesenchymal stem cells in the research field of chronic kidney disease [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2024, 14(02): 73-82.
[5]	Long Zhang, Shanke Sun, Wei Xu, Wenzhu Li, Junda Li, Yongquan Chi, Guangsheng He, Feng Cheng, Xuehao Wang, Jianhua Rao. Clinical efficacy of laparoscopic splenectomy in the treatment of hematological diseases [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 870-875.
[6]	Yongqi Lei, Xinyang Liu, Liyu Yang, Xuehong Tie, Xingxin Yu, Zhida Geng, Yu Liu, Zhengliang Chen, Peng Hui, Yingjian Liang. Perivascular epithelioid cell tumor of the liver complicated with anemia: a case report and literature review [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(05): 710-718.
[7]	Branch of Organ Transplant of Chinese Medical Association, Branch of Organ Transplant Physicians of Chinese Medical Doctor Association. Clinical practice guidelines for kidney injury management of liver transplant recipients in China(2023 edition) [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(03): 276-288.
[8]	Bokai Cheng, Guang Yang. Progress of research on application of hyperinsulinemic-euglycemic clamp technique for assessing insulin resistance in patients with chronic kidney disease [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(06): 334-339.
[9]	Junnan Guo, Hui Lin, Yilin Ren, Xi Qiao. Progress of research on the role of amino acid metabolism disturbance in the transition from AKI to CKD [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(05): 283-287.
[10]	Rongrong Feng, Xiaole Su, Lihua Wang. Research progress on biological markers related to complication of cardiovascular disease in patients with chronic kidney disease [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(05): 273-278.
[11]	Xiaolong Wang, Jie Wu, Shuwei Duan, Chaohui Wang, Na Pan, Yuanyuan Bai, Hangtian Li, Guangyan Cai. Effect of different levels of physical activity on the prognosis of patients with chronic kidney disease [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(03): 121-128.
[12]	Yansheng Wu, Xianwen Zhang, Lin Wang. Research progress on the relationship between intestinal microecology and immunity in patients with chronic kidney disease [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(02): 101-105.
[13]	Beibei Wang, Zhenyi Cui, Jing Wang, Hanyan Wang, Hongzhi Lv, Xiuting Li. Development and Validation of postoperative anemia prediction model in elderly patients with intertro-chanteric fracture [J]. Chinese Journal of Geriatric Orthopaedics and Rehabilitation(Electronic Edition), 2024, 10(06): 355-362.
[14]	Peipei Xi, Jiajun Zhou. Progress in research of sarcopenia in patients with chronic kidney disease: pathogenesis, diagnosis, and treatment [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(05): 491-495.
[15]	Changen Liu, Yan Li, Qide Zhang. Analysis of clinical characteristics of autoimmune gastritis detected by endoscopic screening [J]. Chinese Journal of Gastrointestinal Endoscopy(Electronic Edition), 2024, 11(04): 233-237.

Please choose a citation manager

Content to export